LANDRY BAGWELL: Open Payments
NPI 1356862858 · MONROE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$801 in 48 payments from 16 companies in 2025. Trend: 2023 $470 · 2024 $660 · 2025 $801
Food & beverage: $801
| Company | Payments | Amount |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 12 | $143 |
| Merck Sharp & Dohme LLC | 6 | $117 |
| Novartis Pharmaceuticals Corporation | 6 | $101 |
| SCPHARMACEUTICALS INC. | 4 | $69 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $59 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $58 |
| Amgen Inc. | 2 | $42 |
| CVRx, Inc. | 2 | $39 |
| E.R. Squibb & Sons, L.L.C. | 2 | $34 |
| Novo Nordisk Inc | 2 | $32 |
Products named: OPSUMIT, VERQUVO, LEQVIO, FUROSCIX, JARDIANCE, Kerendia, REPATHA, Barostim Neo System.
Industry payments across LA — which companies pay providers there.
